Darolutamide and health-related QoL in ARAMISIr al contenidoOncologíaDarolutamide and health-related quality of life in patients with nonmetastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial Smith M. et al. European Journal of Cancer 2021:154;138-146Contenido relacionadoEAU-EANM-ESTRO-ESUR-ISUP-SIOG Guías 2022 ICáncer de próstataEAU-EANM-ESTRO-ESUR-ISUP-SIOG Guías 2022 IICáncer de próstataCPRCnm: recomendaciones de manejoCPRCnm
